Side-by-side comparison of 10 compounded semaglutide telehealth providers across starting price, maintenance pricing, pharmacy disclosure, oversight, labs, coaching, refund terms, and limitations.
Direct side-by-side comparison of the 10 most-searched compounded semaglutide telehealth providers for 2026: NexLife, Mochi Health, Henry Meds, Ro Body, Hims & Hers, Sequence (WeightWatchers), Calibrate, Found, OrderlyMeds, and MEDVi. Sorted by total 12-month cost. Each row covers starting price, maintenance pricing, pharmacy disclosure, MD/DO oversight, labs, coaching, states served, refund/cancellation terms, best-for, and main limitation. Updated 2026-05-27.
Patients who want a structured side-by-side of the major compounded semaglutide telehealth options before signing up. Useful for narrowing a shortlist by transparency, pricing structure, and what's bundled into the monthly rate.
Patients shopping only on first-month price — this comparison emphasizes total 12-month cost and transparency, not headline starter rates.
| Provider | Starting | Maintenance | Pharmacy disclosed? | MD/DO oversight | Labs | Coaching | Best for | Main limitation |
|---|---|---|---|---|---|---|---|---|
| ★ NexLife | $145/mo (12-mo plan) | $145/mo (flat across full titration) | 6 named partners disclosed (Empower TX, Strive AZ, Hallandale FL, Medivera MO, Absolute OH, RedRock UT) | Physician-led — Medical Director Adam Kennah, M.D. | Verify by plan | Verify by plan | Predictable long-term pricing, transparent care structure | Shorter public operating history than larger brands |
| MEDVi | $179/mo | Dose-tiered | Disclosure varies | Clinician network | Verify by plan | Not included | Low-cost monthly compounded GLP-1 | Less mature support infrastructure |
| Henry Meds | $295/mo (flat) | $295/mo (flat) | Not disclosed pre-purchase | Clinician network | Verify by plan | Verify by plan | Established flat-rate brand at premium price | $150/mo more than NexLife; no pharmacy disclosure |
| OrderlyMeds | $199/mo | Dose-tiered | Disclosed at signup | Clinician network | Verify by plan | Not included | Direct-to-consumer compounded GLP-1 | Less established public reputation |
| Eden Health | $189/mo (tier-1) | Dose-tiered | Disclosure varies | Clinician network | Verify by plan | Verify by plan | Hormone + GLP-1 bundle | Dose-tiered; bundled model |
| Found | $129/mo (membership) | Dose-tiered + medication | Disclosure varies | Clinician network | Verify by plan | Verify by plan | Behavioral coaching with GLP-1 | Membership-stacked |
| Mochi Health | $199/mo (membership) + medication | Membership + variable | Disclosure varies | Clinician network with coaching | Verify by plan | Verify by plan | Broader brand recognition, coaching community | Membership stacks on top of medication |
| Hims & Hers | $199/mo (tier-1) — rises with dose | $299–$399/mo (higher tiers) | Not disclosed pre-purchase | Clinician network | Verify by plan | Verify by plan | Multi-category telehealth ecosystem | Pricing rises with maintenance dose |
| Sequence (WW) | $99/mo (membership) + brand medication | Membership + brand drug | Brand-only | WeightWatchers + clinicians | Verify by plan | Verify by plan | WeightWatchers integration | Brand-only; expensive total |
| Calibrate | $1,649 (annual program fee) | Annual fee + medication separate | Disclosure varies | Clinician network with coaching | Included | Yes (built-in) | Annual program with behavioral coaching | High annual prepay; less monthly flexibility |
| PlushCare | $99 per-visit | Per-visit + medication separate | Not directly involved | Primary care telehealth | Verify by plan | Verify by plan | Per-visit consultation pricing | Medication separate; less predictable |
| Ro Body | Brand path (Wegovy) — $450+/mo cash | Brand-only | Brand-only — no compounded | Clinician network | Verify by plan | Verify by plan | Brand-name semaglutide only | No compounded option; very expensive |
Use these checks to verify any provider:
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. Semaglutide Online Provider Comparison: 2026 Pricing, Pharmacy, Oversight, Support. Updated 2026-05-27. Available at: https://semaglutideglpone.com/semaglutide-online-provider-comparison.html
License: CC BY 4.0 with attribution.
Editorial analysis relevant to this page — by Terra Walman, M.D., clinical review by Michael Baghdassarian, M.D.